ClinicalTrials.gg
CompletedNCT03308669Updated Nov 27, 2019Results posted

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

A Phase 1 interventional study of Lasmiditan and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected.

Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start of the study and will remain through Day 14.

This study is expected to last approximately 25 days, not including screening. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are healthy males or females (of non-child bearing potential), as determined by medical history and physical examination
  • Have a of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to lasmiditan, topiramate, related compounds or any components of the formulation of lasmiditan or topiramate
  • Have an abnormal supine blood pressure, defined as systolic blood pressure less than (\<) 90 or great (>) 140 millimeters of mercury (mmHg) or diastolic blood pressure \<60 or >90 mmHg at screening
  • Have known or ongoing psychiatric disorders considered by the investigator or demonstrate suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Have a clinically significant abnormality in the neurological examination
  • Have current or a history of orthostatic hypotension (>20-mmHg drop in systolic blood pressure, or >10-mmHg drop in diastolic blood pressure) with or without dizziness and/or syncope at screening or admission to the Clinical Research Unit (CRU) upon repeat testing
  • Have an estimated using Modification of Diet in Renal Disease \<60 milliliter per minute (mL/min) per 1.73 meter squared (m²)
  • Have a history of glaucoma
  • Have a history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Lasmiditan Alone

    Lasmiditan administered orally, alone

    Drug: Lasmiditan

  • Placebo comparator
    Placebo Alone

    Placebo administered orally, alone

    Drug: Placebo

  • Experimental
    Topiramate + Lasmiditan

    Topiramate administered orally, alone, and co-administered with oral lasmiditan

    Drug: Lasmiditan · Drug: Topiramate

  • Experimental
    Topiramate + Placebo

    Topiramate administered orally, alone, and co-administered with oral placebo

    Drug: Placebo · Drug: Topiramate

Interventions

  • Administered orally

    Also known as: LY573144

  • DrugPlacebo

    Administered orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline through Day 24

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Topiramate when administered alone on Day 13 and when coadministered with lasmiditan on Day 14

    Time frame: Day 13 and Day 14: predose,0.5,1,1.5,2,3,4,6,8,12 hours(h)

  2. PK: Maximum Observed Drug Concentration (Cmax) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

    PK: Maximum Observed Drug Concentration (Cmax) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

    Time frame: Day 1 and Day 14: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours

  3. PK: Area Under the Plasma Concentration Versus Time Curve During One Dosing Interval (AUC [Tau]) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14

    PK: Area Under the Plasma Concentration versus Time Curve During One Dosing Interval (AUC \[tau\]) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14

    Time frame: Day 13 and Day 14 - predose,0.5,1,1.5,2,3,4,6,8,12 hours(h)

  4. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

    PK: Area Under the Plasma Concentration versus Time Curve From Zero to Infinity AUC(0-∞) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

    Time frame: Day 1 and Day 14: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours

07

Results

Posted Nov 27, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence 1: 50 mg Topiramate + PlaceboTreatment Sequence 2: 50 mg Topiramate + 200 mg Lasmiditan
Started1020
Received at least one dose of study drug1020
Completed1020
Not completed00

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline through Day 24
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo200 mg LasmiditanTopiramate Alone50 mg Topiramate + 200 mg Lasmiditan50 mg Topiramate + Placebo
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration00000
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Topiramate when administered alone on Day 13 and when coadministered with lasmiditan on Day 14

Time frame:
Day 13 and Day 14: predose,0.5,1,1.5,2,3,4,6,8,12 hours(h)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14
Nanogram/milliliter (ng/mL)50 mg Topiramate50 mg Topiramate + 200 mg Lasmiditan
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 144300 ± 154190 ± 16
SecondaryPK: Maximum Observed Drug Concentration (Cmax) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

PK: Maximum Observed Drug Concentration (Cmax) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

Time frame:
Day 1 and Day 14: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
PK: Maximum Observed Drug Concentration (Cmax) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14
Nanogram/milliliter (ng/mL)200 mg Lasmiditan50 mg Topiramate + 200 mg Lasmiditan
PK: Maximum Observed Drug Concentration (Cmax) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14276 ± 41301 ± 35
SecondaryPK: Area Under the Plasma Concentration Versus Time Curve During One Dosing Interval (AUC [Tau]) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14

PK: Area Under the Plasma Concentration versus Time Curve During One Dosing Interval (AUC \[tau\]) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14

Time frame:
Day 13 and Day 14 - predose,0.5,1,1.5,2,3,4,6,8,12 hours(h)
Reported as:
Geometric mean · nanograms*hour per milliliter(ng*h/mL)
PK: Area Under the Plasma Concentration Versus Time Curve During One Dosing Interval (AUC [Tau]) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 14
nanograms*hour per milliliter(ng*h/mL)50 mg Topiramate50 mg Topiramate + 200 mg Lasmiditan
PK: Area Under the Plasma Concentration Versus Time Curve During One Dosing Interval (AUC [Tau]) of Topiramate When Administered Alone on Day 13 and When Coadministered With Lasmiditan on Day 1442600 ± 1542800 ± 17
SecondaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

PK: Area Under the Plasma Concentration versus Time Curve From Zero to Infinity AUC(0-∞) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14

Time frame:
Day 1 and Day 14: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours
Reported as:
Geometric mean · nanograms*hour per milliliter(ng*h/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 14
nanograms*hour per milliliter(ng*h/mL)200 mg Lasmiditan50 mg Topiramate + 200 mg Lasmiditan
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of Lasmiditan When Administered Alone on Day 1 and When Coadministered With Topiramate on Day 141860 ± 292050 ± 29

Adverse events

Collected over Up To 24 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Lasmiditan0/20 (0%)0/20 (0%)8/20 (40%)
Placebo0/10 (0%)0/10 (0%)3/10 (30%)
Topiramate Alone0/30 (0%)0/30 (0%)5/30 (16.7%)
50 mg Topiramate + 200 mg Lasmiditan0/20 (0%)0/20 (0%)8/20 (40%)
50 mg Topiramate + Placebo0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
Event200 mg LasmiditanPlaceboTopiramate Alone50 mg Topiramate + 200 mg Lasmiditan50 mg Topiramate + Placebo
DizzinessNervous system disorders7/201/100/305/201/10
SomnolenceNervous system disorders2/200/102/303/200/10
Lip dryGastrointestinal disorders0/201/100/300/200/10
FatigueGeneral disorders1/201/101/300/200/10
Depressed moodPsychiatric disorders0/200/100/300/201/10
Euphoric moodPsychiatric disorders2/201/101/301/200/10
ScratchInjury, poisoning and procedural complications0/200/102/300/200/10
Disturbance in attentionNervous system disorders0/200/102/301/200/10

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: 50 mg Topiramate + PlaceboTreatment Sequence 2: 50 mg Topiramate + 200 mg LasmiditanTotal
Mean44.3 ± 13.344.0 ± 13.644.1 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: 50 mg Topiramate + PlaceboTreatment Sequence 2: 50 mg Topiramate + 200 mg LasmiditanTotal
Female011
Male101929
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: 50 mg Topiramate + PlaceboTreatment Sequence 2: 50 mg Topiramate + 200 mg LasmiditanTotal
Hispanic or Latino011
Not Hispanic or Latino101929
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: 50 mg Topiramate + PlaceboTreatment Sequence 2: 50 mg Topiramate + 200 mg LasmiditanTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American11011
White9817
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence 1: 50 mg Topiramate + PlaceboTreatment Sequence 2: 50 mg Topiramate + 200 mg LasmiditanTotal
United States102030
08

Study locations

1 site
  • Covance Madison CRU
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2017, 1 month.

Results were first posted in Nov 2019, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2017
First posted
Oct 12, 2017
StartActual
Oct 16, 2017
Primary completionActual
Dec 2, 2017
CompletionActual
Dec 2, 2017
Results first posted
Nov 27, 2019
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03308669
Responsible party
Sponsor
First posted
Oct 12, 2017
Start date
Oct 16, 2017
Primary completion
Dec 2, 2017
Completion
Dec 2, 2017
Results posted
Nov 27, 2019
Last update
Nov 27, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lasmiditan · Topiramate

Start the discussion